Xtandi® (enzalutamide) – Expanded indication and new warnings
July 13, 2018 - Astellas Pharma and Pfizer announced the FDA approval of Xtandi (enzalutamide), for the treatment of patients with castration-resistant prostate cancer (CRPC).
Download PDF
